Therapeutic Areas |
Psychiatry
Psychiatry
|
Latuda® (lurasidone HCI)
Psychiatry
|
Resources
Psychiatry
|
Disease State
Psychiatry
|
Disease State
|
Bipolar Depression
Psychiatry
|
Disease State
|
Schizophrenia
Psychiatry
|
Disease State
|
General Psychiatry
Psychiatry
|
Latuda® (lurasidone HCI)
|
Publications
Therapeutic Areas |
Neurology
Neurology
|
Aptiom® (eslicarbazepine acetate)
Neurology
|
Kynmobi® (apomorphine hydrochloride)
Neurology
|
Resources
Neurology
|
Disease State
Neurology
|
Disease State
|
Parkinson's
Neurology
|
Disease State
|
Epilepsy
Neurology
|
Disease State
|
General Neurology
|
Publications
|
Publications
Therapeutic Areas |
Respiratory
Respiratory
|
Brovana® (arformoterol tartrate)
Respiratory
|
Lonhala® Magnair® (glycopyrrolate)
Respiratory
|
Xopenex HFA® (levalbuterol tartrate)
Respiratory
|
Resources
Respiratory
|
Disease State
Respiratory
|
Disease State
|
COPD
Respiratory
|
Disease State
|
General Respiratory
|
Publications
|
Publications
|
Publications
Submit Medical Inquiry
Engage With Field Medical
Resources
Adverse Event & Product Complaint Reporting
Pipeline
| SEP-363856
| SEP-363856 | Schizophrenia 4 Weeks
| SEP-363856 | Schizophrenia 26 Weeks
| SEP-363856 | PD Psychosis 6 Weeks
| SEP-4199
| SEP-4199 | 6 Week
Search Medical Information
Scientific Conferences
Search Medical Information
Psychiatry
Neurology
Respiratory
Home
Therapeutic Area
Psychiatry
Neurology
Respiratory
submit medical inquiry
Engage With Field Medical
resources
adverse event & product complaint reporting
pipeline
back
LONHALA® MAGNAIR® (glycopyrrolate)
As of June 30, 2023, Sunovion will voluntarily withdraw Lonhala
®
Magnair
®
(glycopyrrolate) Inhalation Solution from the U.S. market, due to limited utilization.
Prescribing Information
Read More
Patient Information
Read More
Instructions for Use
Video
Read More
Publications
Read More
Graphical Abstracts
Read More
medication guide
LONHALA MAGNAIR Instructions for Use
opt-in to communications from Sunovion
First Name
Last Name
Email
Phone Number
By checking this box, I agree and acknowledge that the information I’ve provided voluntarily will be used only by Sunovion and its contracted third-parties to contact me regarding my request. I understand that Sunovion will not sell or transfer my name to any third party for their marketing use. Please see the most recent version of our privacy notice, which may change from time to time.
Submit
contact us
Sunovion Pharmaceuticals Inc.
Medical Information
84 Waterford Drive
Marlborough, MA 01752
1-800-739-0565
minfo@sunovion.com
Global Medical Information
CANADA
Sunovion Pharmaceuticals Canada Inc.
Medical Information
1-866-260-6291, option 2
sunovionmedinfo@solutionsinhealth.com
OTHER COUNTRIES
Sunovion Pharmaceuticals Inc.
Medical Information
800-739-0565
minfo@sunovion.com
For information about the collection and use of your personal information, please visit
www.sunovion.com/HCPprivacynotice
THANK YOU
Thank you for rating SunovionMedical.com
close
HCP/FDM Confirmation
Please confirm below to continue
I confirm that I am a Health Care Professional (HCP) practicing in the United States, or acting on behalf of an HCP
OR
I am a Formulary Decision Maker (FDM) and/or working on behalf of a public or private payer organization to review scientific information to make drug or device selection or acquisition, formulary management, or coverage and reimbursement decisions on a population basis.
YOU ARE NOW LEAVING SUNOVIONMEDICAL.COM
You are now leaving SunovionMedical.com
ok
cancel
back
are registered trademarks of Sumitomo Pharma Co., Ltd.
, used under license.
